Greater than one-third of adults in the United States have metabolic syndrome (MetS), a cluster of risk factors highly associated with the development of cardiovascular diseases. Premature vascular dysfunction in MetS may lead to accelerated age-related atherogenesis and arterial stiffening, thereby increasing cardiovascular risk. Montmorency tart cherries (Prunus cerasus L.) are rich in bioactive compounds, such as anthocyanins, known to exert cardiovascular protective effects. Previous research suggests that tart cherry juice consumption may improve cardiovascular health. The objective of this study was to evaluate the effects of daily consumption of tart cherry juice on hemodynamics, arterial stiffness, and blood biomarkers of cardiovascular and metabolic health in men and women with MetS. In a randomized, single-blind, placebo-controlled, parallel-arm pilot clinical trial, 19 men and women 20 to 60 years of age with MetS consumed 240 mL of tart cherry juice (Tart Cherry; n = 5 males, 4 females) or an isocaloric placebo-control drink (Control; n = 5 males, 5 females) twice daily for 12 weeks. Arterial stiffness (pulse wave velocity), brachial and aortic blood pressures, wave reflection (augmentation index), and blood biomarkers of cardiovascular and metabolic health were assessed at baseline and 6 and 12 weeks. Oxidized low-density lipoprotein and soluble vascular cell adhesion molecule-1 were significantly lower (P = .047 and P = .036, respectively) in Tart Cherry than Control at 12 weeks, but were not significantly lower than baseline values. There was a trend for total cholesterol to be lower (P = .08) in Tart Cherry than Control at 12 weeks. No significant changes were observed in hemodynamics, arterial stiffness, or other blood biomarkers assessed. These results suggest that daily tart cherry consumption may attenuate processes involved in accelerated atherogenesis without affecting hemodynamics or arterial stiffness parameters in this population. The pilot nature of this study warrants interpreting these findings with caution, and future clinical trials with a larger sample size are needed to confirm these findings.

中文翻译：

---

食用蒙莫朗西酸樱桃汁对代谢综合征成人心脏代谢生物标志物的影响：随机对照试点试验。


美国超过三分之一的成年人患有代谢综合征 (MetS)，这是一组与心血管疾病的发展高度相关的危险因素。 MetS 中的过早血管功能障碍可能导致加速与年龄相关的动脉粥样硬化和动脉硬化，从而增加心血管风险。蒙莫朗西酸樱桃 ( Prunus cerasus L.) 富含生物活性化合物，例如花青素，已知具有心血管保护作用。先前的研究表明，饮用酸樱桃汁可能会改善心血管健康。本研究的目的是评估每日饮用酸樱桃汁对患有 MetS 的男性和女性的血流动力学、动脉僵硬度以及心血管和代谢健康的血液生物标志物的影响。在一项随机、单盲、安慰剂对照、平行试验临床试验中，19 名 20 至 60 岁患有 MetS 的男性和女性饮用了 240 mL 酸樱桃汁（Tart Cherry； n = 5 名男性，4 名女性）或等热量安慰剂对照饮料（对照； n = 5 名男性，5 名女性），每天两次，持续 12 周。在基线、第 6 周和第 12 周评估动脉僵硬度（脉搏波速度）、肱动脉血压和主动脉血压、波反射（增强指数）以及心血管和代谢健康的血液生物标志物。 12 周时，酸樱桃中的氧化低密度脂蛋白和可溶性血管细胞粘附分子 1 显着低于对照（分别为P = .047 和P = .036），但并不显着低于基线值。 12 周时，酸樱桃中的总胆固醇有低于对照的趋势 ( P = .08)。 血流动力学、动脉僵硬度或其他血液生物标志物评估没有观察到显着变化。这些结果表明，每天食用酸樱桃可能会减弱参与加速动脉粥样硬化形成的过程，而不影响该人群的血流动力学或动脉僵硬度参数。这项研究的试点性质需要谨慎解释这些发现，未来需要更大样本量的临床试验来证实这些发现。